America’s pharma sector has asked US Trade Representative (USTR) to continue to keep India on its priority watch list (PWL) which includes countries that are alleged violators of US patent laws, claiming that the environment on the ground remains “challenging” in India.
Among the key issues of concern for the US pharma sector in India are unpredictable IP environment, high tariffs and taxes on medicines, regulatory data protection failure, discriminatory and non-transparent market access policies and unpredictable environment for clinical research.
Pharmaceutical Research and Manufacturers of America (PhRMA) in a submission requested US Trade Representative (USTR) to continue to keep India on the Priority Watch List in the 2017 Special 301 Report.
“Further, we urge USTR to provide an opportunity for a meaningful assessment of India’s IP regime through an Out-of-Cycle Review, so that the US government can evaluate progress on these important issues and dedicate the required bilateral attention necessary to translate India’s commitments into substantive and real policy change that addresses the IP and market access barriers confronted by US businesses in India,” PhRMA said in the Indian section of its submission.
Continued attention to IP and market access barriers in India has sent a strong signal of the importance of these issues to the bilateral relationship, has fueled constructive industry-government dialogue, and has been critical in preventing further deterioration of the innovation environment in that country, it said.
Nevertheless, many of the same issues remain and no meaningful action has been taken to address the unpredictability in IP protection and enforcement that remains, it said.
In its submission to USTR’s Special 301 Review, PhArma said it supports the Indian Government’s efforts to create a stronger business, innovation and healthcare environment through the “Make in India” initiative, the new National Intellectual Property Rights (IPR) Policy and the forthcoming National Health Policy.
“These efforts can advance improved access to healthcare for Indian patients, while driving economic growth by enhancing India’s global competitiveness and improving ease of doing business. However, despite some positive signs, PhRMA’s members remain concerned about the challenging policy environment in India,” PhARMA said in its submission to US Trade Representatives last week.
Pharmaceutical innovators, it said saw positive signs from the Indian Government in 2016. However, these signals have not yet been translated into real policy and practical change.
“To research, develop and deliver new treatments and cures to patients, bio pharmaceutical innovators must be able to secure and effectively enforce intellectual property (IP) rights,” the report said, adding that with the right policies put in place, India could one day become a globally-competitive leader in life sciences and biomedical development.